Scilex Holding Co (SCLX) stock

SCLXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLXW

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30

$1.56−0.06 (-3.70%)

Close on Nov 12, 2026Market cap $13.25MP/E –Yield –

Scilex EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Scilex has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SCLX.

Revenue growth-28.5% · median 158.4%

Gross margin161.1% · median 89.3%

Operating margin-1136.4% · median -147.4%

Net margin-1469.8% · median -161.8%

Advertisement
300 × 250

See a number that looks wrong?